MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study

Plain-language summary

This follow-up study examines how metabolic dysfunction-associated steatotic liver disease (MASLD) develops in people with type 2 diabetes in a primary care setting. It includes people aged 18 and over who previously took part in the EPSONIP trial (NCT03864510). It is a study without an assigned phase and enrolls participants by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Linkoeping University

Start date

12/16/2025

Estimated completion

12/31/2034

Countries

Sweden

Related genes

Locations

• Linköping, Sweden

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Previously included and fulfilled evaluation in EPSONIP trial (NCT03864510)
* Age \>/= 18 years
* Informed consent

Exclusion Criteria:

* Contraindication to magnetic resonance
* Other primary liver disease than MASLD diagnosed after inclusion EPSONIP trial (NCT03864510)
* Liver transplantation